News Column

German Heart Group Verifies Accuracy of Ventripoint's VMS(TM) Heart Analysis Technology for Cardiac MRI and 3D Echocardiography Imaging

July 7, 2014



SEATTLE, WASHINGTON--(Marketwired - July 7, 2014) - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) announces that a group led by Dr. Kai Laser at the Center for Congenital Heart Defects, Bad Oeynhausen, Germany, has published the results of a clinical study that demonstrates the robust application of the VMS heart analysis technology beyond 2D ultrasound imaging in a wide range of cardiac conditions.

"The Ventripoint approach to analyzing the right ventricle of the heart works for all types of scanning and gives rapid, accurate and important results for the diagnoses and management of patients with a wide spectrum of complex cardiac conditions," stated Dr. Laser.

For the first time, this study shows that the bias often reported between MRI and echocardiography results are due to analysis technique and not imaging modality. In the study all three imaging modalities: 2D-echo, 3D echo and cardiac MRI gave the same results when analyzed using the VMS technique and were equivalent to the gold-standard MRI analysis using the method of disks. Historically, the comparison of echocardiography and cardiac MRI analysis has been discouraged due to unexplained discrepancies. This is an important consideration when trying to assess a patient's progress over time where multiple imaging modalities may have been used in the past. Standardization using the VMS technique for all images would give comparable longitudinal results and allow for better patient monitoring and treatment decisions.

The study also showed that the time to complete the analysis on these complex cases was reduced to 5 minutes using the VMS approach compared to 10 to 30 minutes using conventional techniques.

A report has been accepted for publication in the Journal of the American Society of Echocardiography and is entitled "Knowledge-Based Reconstruction of Right Ventricular Volumes Using Real-time Three-dimensional Echocardiographic as Well as Cardiac Magnetic Resonance Images: Comparison with a Cardiac Magnetic Resonance Standard." This study further validates the VMS approach as accurate and reliable for analyzing MRI images or 3D ultrasound images, when adequate quality images can be acquired.

"This study, by an independent group, shows how the VMS technology can be applied across multiple imaging modalities and provides accurate and equivalent results for Right Ventricular function," stated Dr. George Adams, CEO of Ventripoint. "This ability of the VMS greatly increases our market potential, as it allows us to seek partners who would integrate the VMS approach into MRI and 3D-echocardiography analysis packages, while continuing to market VMS for routine 2D-echocardiography."

About the Journal of the American Society of Echocardiography

The Journal of the American Society of Echocardiography, with a monthly print and digital distribution of over 50,000, is considered the top-tier publication for peer-reviewed studies related to cardiac ultrasound imaging.

About Ventripoint Diagnostics Ltd.

Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS(TM) is the first cost-effective and accurate tool for measuring right ventricle heart function. The Corporation has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at www.sedar.com. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

FOR FURTHER INFORMATION PLEASE CONTACT: Ventripoint Diagnostics Ltd. Dr. George Adams CEO (206) 910-9125 gadams@ventripoint.com Source: Ventripoint Diagnostics Ltd.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Marketwire (Canada)


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters